WuHan Dong Kang Yuan Technology co., LTD

Integrity-based service-oriented Kangyuan products must be boutiques.

Sales & Support
Request A Quote - Email

Select Language

English
French
German
Italian
Russian
Spanish
Portuguese
Dutch
Greek
Japanese
Korean
Arabic

Home
Products
About Us
Factory Tour
Quality Control
Contact Us
Request A Quote

: All Categories Active Pharmaceutical Ingredients Hair Loss Treatment Powder Estrogen Hormone Raw Material Steroid Hormone Powder Nootropic Powder Caine Series Pharma Raw Materials Cosmetic Raw Materials Skin Care Raw Materials Pharmaceutica API Powder Veterinary Raw Material Vitamin Raw Material Amino Acid Powder Disinfectant Raw Material Pharmaceutical Intermediates Chemical Raw Materials

Home Products Steroid Hormone Powder

10540-29-1 White Tamoxifen Powder For Oral Tablets

All Products

Active Pharmaceutical Ingredients (37)

Hair Loss Treatment Powder (13)

Estrogen Hormone Raw Material (51)

Steroid Hormone Powder (217)

Nootropic Powder (32)

Caine Series Pharma Raw Materials (42)

Cosmetic Raw Materials (18)

Skin Care Raw Materials (23)

Pharmaceutica API Powder (118)

Veterinary Raw Material (16)

Vitamin Raw Material (13)

Amino Acid Powder (13)

Disinfectant Raw Material (6)

Pharmaceutical Intermediates (37)

Chemical Raw Materials (29)

I'm Online Chat Now

Integrity-based, service first, DKY produced, will be a boutique.

—— Mr John

10540-29-1 White Tamoxifen Powder For Oral Tablets

Large Image : 10540-29-1 White Tamoxifen Powder For Oral Tablets Get Best Price

Product Details:

Place of Origin:	hubei
Brand Name:	DKY
Certification:	COA
Model Number:	10540-29-1

Payment & Shipping Terms:

Minimum Order Quantity:	10g
Packaging Details:	1kg/bag or 100g/bag
Delivery Time:	5-7 work days
Payment Terms:	T/T, Western Union, MoneyGram
Supply Ability:	1000kg per year

Contact Now

Detailed Product Description

CAS No:	10540-29-1	Molecular Formula:	C26H29NO
Molecular Weight:	371.51	EINECS No:	234-118-0
Melting Point:	97-98 ° C	Boiling Point:	501.18 ° C
Density:	1.042 G/cm3	Flash:	140° C
Refractive Index:	1.582	Storage Conditions:	2-8°C
Steam Pressure:	1.85E-09mmHg At 25°C	Appearance:	Fine Gray-white Crystalline Powder
High Light:	10540-29-1 , nolvadex powder

Tamoxifen/Nolvadex/Ledertam 10540-29-1 white powder for oral tablets

Basic parameter:

Product Name :Tamoxifen

Product alias: Tamoxiphen; TAMOXIFEN. TAMOXIFENBASE; TRANS - 2 - (4 - (1, 2 - DIPHENYL - 1 - BUTENYL) PHENOXY] - N, N - DIMETHYLETHYLAMINE; (Z) -, 2 - [4 - (1, 2 - DIPHENYL - 1 - BChemicalbookUTENYL) PHENOXY] - N, N - DIMETHYLETHANAMINE; [Z] 1 - [P - DIMETHYLAMINOETHOXYPHENYL] - 1, 2 - DIPHENYL - 1 - BUTENE; Genox; Tamoxen

CAS no.: 10540-29-1

Molecular formula: C26H29NO

Molecular weight: 371.51

EINECS no. : 234-118-0

Melting point: 97-98 ° C

Boiling point: 501.18 ° C

Density: 1.042 g/cm3

Flash: 140 DHS C

Refractive index: 1.582

Storage conditions: 2-8 C

Steam pressure: 1.85E-09mmHg at 25°C

Solubility: H2O:in · Day 20°C

Storage conditions: 2-8°C

Appearance: Fine gray-white crystalline powder

Certificate of Analysis:

Product Name	Tamoxifen	Batch No	2019.10.10
Quantity	100KGS	MFG. Date	2019.10.10
Test Date	2019.10.10	Exp Date	2021.10.09
Quality standard	enterprise standard
Test Items	Specification		Test Results
Description	White crystalline powder		Pass
Melting drying	95-98℃		95.2-97.6℃
Assay(on dry basis)	≥99.0%		99.23%
Loss on drying	Not more than 0.5%		0.23%
Residue on ignition	Not more than 0.2%		0.06%
iron	Not more than 0.05%		0.008%
Heavy metals	Not more than 0.001%		0.0006%
E-isonet	Not more than 0.3%		0.2%
Conclusion	comforms to enterprise standard

Product shooting:

Application:

Appropriate population and duration of Tamoxifen use:

1) One of the standard programs of adjuvant endocrine therapy for premenopausal patients.

2) For premenopausal women with a moderate to high risk of recurrence (young breast cancer patients with high histologic grade and lymph node involvement), Tamoxifen or aromatase inhibitors combined with oophorectomy or ovarian suppression for 5 years may be considered.

3) Aromatase inhibitors can be switched to Tamoxifen therapy if the patient is menopausal.

4) The third-generation aromatase inhibitors are preferred in postmenopausal patients, and initiation is recommended.

5) Postmenopausal patients who cannot tolerate aromatase inhibitors may still choose tamoxifen.

Tamoxifen can also be used in the following ways:

1) Prevention of breast cancer in high-risk women;

2) As an adjuvant therapy for breast cancer metastasis after surgery to prevent recurrence;

3) Treatment of metastatic breast cancer

4) Patients with ductal carcinoma in situ are treated with surgery and radiation to reduce their risk of progression to invasive breast cancer.

I am Angela

Contact Angela, you would never regret.

email: zs@dkybpc.com

Tel: +86-15377658509, you can add me on WeChat or Skype or Whatsapp if you are using that.